Expert panel likely to take call on Sputnik V vaccine at key meet today

Russia registered Sputnik V for public use in August, the first country to do so

Sputnik
A paramedic holds a pack of used and unused vials of Russia's Sputnik V coronavirus disease vaccine at a private hospital in Karachi (Photo: Reuters)
ANI General News
2 min read Last Updated : Apr 12 2021 | 2:51 PM IST

The Subject Expert Committee (SEC) is likely to meet today to take up Sputnik V application for Emergency Use Authorisation (EUA) in India, said sources.

Russia's Sputnik V vaccine did not get the EUA on Thursday as the SEC, following the meeting, asked for more information.

According to the sources, 'The SEC has asked for more information in context with the approval of the Russian vaccine."

The committee, set up by the government, looked into Dr Reddy's application seeking approval for the vaccine to be used in India. The Russian vaccine has an effectiveness of 91.6 per cent. Dr Reddy's Lab has partnered with the Russia Direct Investment Fund (RDIF) to bring the Sputnik V vaccine to India and other countries.

Russia registered Sputnik V for public use in August, the first country to do so, though the approval came before the start of the large-scale trial in September.

Top government sources told ANI that by end of the third quarter of this year, India will be getting vaccines from five additional manufacturers. India currently manufactures Covishield and Covaxin.

When a top-level source was asked when the vaccines will be available for use, he said, "Sputnik is expected to be available latest by June, if all goes well Johnson and Johnson ( Bio E) will be available by August, Cadilla Zydus will also be available by August, Novavex (Serum) by September and Nasal Vaccine (Bharat) by October."

The Government is making all efforts to accelerate the progress without cutting any corners in research, development, and clinical trial stages, the source added.

India is currently facing the second wave of COVID-19 pandemic with the number of new cases increasing each day.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineCoronavirus Tests

First Published: Apr 12 2021 | 2:49 PM IST

Next Story